Evidence map›Paper›PMID 39678894›Full record

ArticleJournal of thoracic disease2024

Assessment of tumor biomarkers for prognosis in interstitial lung disease associated with connective tissue disease: a prospective study.

Yuanying Wang, Di Sun, Yawen Song, Xuqin Du, Na Wu, Qiao Ye

Abstract read
In one paragraph

Article in Journal of thoracic disease, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Review
  3. Article
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Yuanying WangClinical Center for Interstitial Lung Diseases, Beijing Institute of Respiratory Medicine and Beijing Chao-Yang Hospital, Capital Medical University, Beijing, China.
Di SunClinical Center for Interstitial Lung Diseases, Beijing Institute of Respiratory Medicine and Beijing Chao-Yang Hospital, Capital Medical University, Beijing, China.
Yawen SongClinical Center for Interstitial Lung Diseases, Beijing Institute of Respiratory Medicine and Beijing Chao-Yang Hospital, Capital Medical University, Beijing, China.
Xuqin DuClinical Center for Interstitial Lung Diseases, Beijing Institute of Respiratory Medicine and Beijing Chao-Yang Hospital, Capital Medical University, Beijing, China.
Na WuClinical Center for Interstitial Lung Diseases, Beijing Institute of Respiratory Medicine and Beijing Chao-Yang Hospital, Capital Medical University, Beijing, China.
Qiao YeClinical Center for Interstitial Lung Diseases, Beijing Institute of Respiratory Medicine and Beijing Chao-Yang Hospital, Capital Medical University, Beijing, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: There is uncertainty with respect to the baseline tumor markers and clinical outcomes for patients with connective tissue disease-associated interstitial lung disease (CTD-ILD). The study aimed to assess the association between baseline tumor markers and progressive pulmonary fibrosis (PPF) and prognosis. Methods: This is a prospective cohort study. Serum levels of nine tumor markers, including carcinoembryonic antigen (CEA) and carbohydrate antigen 125 (CA125), neuron-specific enolase (NSE), squamous cell carcinoma (SCC) antigen, cytokeratin fraction 21-1 (CYFRA21-1), serum ferritin (SF), alpha-fetoprotein (AFP) and carbohydrate antigen 724 (CA724) were collected at baseline in patients with CTD-ILD and healthy controls (HCs). Logistic regression and receiver operating characteristic (ROC) curves were used to assess the strength of baseline tumor markers in identifying PPF in CTD-ILD. Correlation analysis was performed to explore associations between tumor markers and disease severity. The relationship of prognosis and these markers was also evaluated. Results: There were 224 patients with CTD-ILD and 63 HCs included in the analysis. The serum CEA and CA125 levels were significantly higher in the PPF group than in the non-PPF and HC groups. The area under the ROC curve (AUC) of CEA was 0.64 [95% confidence interval (CI): 0.56-0.72], the highest among the tested tumor markers. For CA125, the AUC was 0.59 (95% CI: 0.51-0.68). Patients were then stratified into low-titre and high-titre groups based on the median levels of CEA or CA125. Compared with the low CEA group, patients in the high CEA group showed a higher risk for PPF [odds ratio (OR): 3.42, 95% CI: 1.74-6.72, P<0.001], while compared with the low CA125 group, patients in the high CA125 group had an OR of 1.96 (95% CI: 1.08-3.55, P=0.03). Elevated CEA concentration remained a significant risk factor of PPF in multivariate analysis, but CA125 did not. Furthermore, elevated CEA levels was also an independent risk factor associated with all-cause mortality and acute exacerbation (AE) in CTD-ILD patients. Conclusions: Circulating CEA may be associated with pulmonary fibrosis progression and prognosis of CTD-ILD.

Indexed as

connective tissue disease (CTD)interstitial lung diseases (ILDs)prognosisPulmonary fibrosistumor markers

Identifiers

PMID39678894
PMCPMC11635275

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.